Latest Stories
2 Mid-Cap Stocks to Consider Right Now and 1 We Find Risky
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
3 Reasons PUBM is Risky and 1 Stock to Buy Instead
PubMatic has gotten torched over the last six months - since July 2025, its stock price has dropped 41.4% to $7.49 per share. This might have investors contemplating their next move.
3 Reasons to Sell QLYS and 1 Stock to Buy Instead
Over the past six months, Qualys’s shares (currently trading at $131.91) have posted a disappointing 5.5% loss, well below the S&P 500’s 10% gain. This might have investors contemplating their next move.
Rush Enterprises (RUSHA): Buy, Sell, or Hold Post Q3 Earnings?
Rush Enterprises has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.3%. The stock now trades at $62.68, marking a 24.3% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
3 Reasons to Avoid DHR and 1 Stock to Buy Instead
Danaher’s 24.7% return over the past six months has outpaced the S&P 500 by 14.7%, and its stock price has climbed to $234.55 per share. This performance may have investors wondering how to approach the situation.
AXIS Capital (AXS): Buy, Sell, or Hold Post Q3 Earnings?
AXIS Capital trades at $103.18 and has moved in lockstep with the market. Its shares have returned 7.4% over the last six months while the S&P 500 has gained 10%.
3 Reasons to Sell SEMR and 1 Stock to Buy Instead
Over the past six months, Semrush has been a great trade, beating the S&P 500 by 21.4%. Its stock price has climbed to $11.91, representing a healthy 31.4% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
2 Reasons to Watch INSP and 1 to Stay Cautious
What a brutal six months it’s been for Inspire Medical Systems. The stock has dropped 24.3% and now trades at $94.73, rattling many shareholders. This might have investors contemplating their next move.
2 Reasons to Watch ELV and 1 to Stay Cautious
Elevance Health’s 33.1% return over the past six months has outpaced the S&P 500 by 23.1%, and its stock price has climbed to $368.00 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.